Wire · opportunities
Medibyt Receives FDA 510(k) Clearance for CPETWise, Advancing Cardiopulmonary ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
Medibyt has received FDA 510(k) clearance for CPETWise, enabling U.S. commercialization of its cardiopulmonary exercise test analysis platform. The company is advancing AI capabilities, expanding strategic partnerships, and plans to enter international markets and additional cardiopulmonary diagnostics.
This Wire brief sits within Fusion42's coverage of Digital Health, and 5 sources have reported it between 1 Sep 2026 and 4 Sep 2026.
◆ ◆ The Wire takeaway
Cardiopulmonary diagnostics founders now have a clear path to US market entry with FDA clearance removing a major barrier. You can accelerate your product's clinical adoption by aligning with Medibyt’s expanding partnerships and AI-powered automation in CPET workflows.
◆ Coverage
5 sources · first reported 1 Sep 2026 · latest 4 Sep 2026
◆ Related on Wire
◆ Topics